Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease

Topic: Inflammation, microglia and astrocytes

Parkinson's disease (PD) is second only to Alzheimer's disease as the most common devastating human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. We investigated whether simvastatin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to model PD in mice. First, MPP(+) induced the activation of p21(ras) and nuclear factor-kappaB (NF-kappaB) in mouse microglial cells. Inhibition of MPP(+)-induced activation of NF-kappaB by Deltap21(ras), a dominant-negative mutant of p21(ras), supported the involvement of p21(ras) in MPP(+)-induced microglial activation of NF-kappaB. Interestingly, simvastatin attenuated activation of both p21(ras) and NF-kappaB in MPP(+)-stimulated microglial cells. Consistently, we found a very rapid activation of p21(ras) in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice. However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21(ras), attenuated nigral activation of NF-kappaB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflammatory responses and protected dopaminergic neurons in MPTP-intoxicated mice, but at levels less than simvastatin. Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model. Therefore, we conclude that statins may be of therapeutic benefit for PD patients.

Key findings

• Consistently, we found a very rapid activation of p21(ras) in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice.
• These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice.
• Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model.
• Therefore, we conclude that statins may be of therapeutic benefit for PD patients.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1523/jneurosci.4144-09.2009
• PubMed: 19864567
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{ghosh2009-19864567,
  author  = {Ghosh, A. and Roy, A. and Matras, J. and Brahmachari, S. and Gendelman, H. E. and Pahan, K.},
  title   = {{Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease}},
  journal = {The Journal of neuroscience : the official journal of the Society for Neuroscience},
  year    = {2009},
  doi     = {10.1523/jneurosci.4144-09.2009},
  pmid    = {19864567},
  url     = {https://doi.org/10.1523/jneurosci.4144-09.2009}
}

Related studies in Drug development

• Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model PloS one · 2013-03-11 · usefulness score 40/100
• Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease Molecular psychiatry · 2009-07-21 · usefulness score 40/100
• Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Neuroscience · 2015-07-02 · usefulness score 36/100
• A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF Brain research · 2015-10-11 · usefulness score 36/100
• Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons FEBS letters · 1997-07-01 · usefulness score 36/100
• Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007-11-01 · usefulness score 36/100

Also tagged “expressed”

384 studies in the library carry the topic tag “expressed”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 384 tagged studies.

• The TREM-receptor family interactome in the human brain bioRxiv · 2026-10-29 · usefulness score 16/100 · Genetics
• Mechanistic study of PHLDA1 in cognitive dysfunction of Alzheimer’s disease model mice via FoxO1‑mediated neuroinflammation Research Square · 2026-10-12 · usefulness score 16/100 · Biomarkers
• Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease Nature neuroscience · 2023-02-06 · usefulness score 47/100 · Genetics

Similar studies

• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention 2010 · Inflammation and the immune system
• Statins: mechanisms of neuroprotection 2009 · Drug development
• Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? 2007 · Risk factors
• Probenecid relieves LPS-induced neuroinflammation by modulating the NLRP1 inflammasome pathway in BV2 cells 2025 · Inflammation and the immune system
• Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling 2021 · Inflammation and the immune system
• Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease 2008 · Drug development

More on Drug development

• A review that covers this ground Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy · 2003-07-01 · usefulness score 71/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →